Wanbangde Pharmaceutical Holding Group Co., Ltd.

Equities

002082

CNE000001P94

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
4.7 CNY +1.95% Intraday chart for Wanbangde Pharmaceutical Holding Group Co., Ltd. +10.59% -26.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wanbangde Pharmaceutical Holding Group Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Wanbangde Pharma Elects Vice Chairman, Appoints CFO MT
Wanbangde Pharma's Anesthesia Passes Drug Regulator's Consistency Evaluation MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.(XSEC:002082) added to S&P Global BMI Index CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Board Appointments CI
Wanbangde Pharmaceutical Registers New Medical Device MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 05 June 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Approves Cash Dividend for the Year 2022 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Announces Final Profit Distribution Proposal for 2022 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.(XSEC:002082) dropped from S&P Global BMI Index CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Wanbangde Pharma in Talks to Buy Controlling Stake in Consun Pharma MT
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021. CI
Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback announced on March 15, 2021, has expired with 5,000,000 shares, representing 0.81% for CNY 59.98 million. CI
Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021. CI
Wanbangde Pharmaceutical Holding Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tranche Update on Wanbangde Pharmaceutical Holding Group Co., Ltd.'s Equity Buyback Plan announced on March 15, 2021. CI
Chart Wanbangde Pharmaceutical Holding Group Co., Ltd.
More charts
Wepon Pharmaceutical Holding Group Co Ltd, formerly Wanbangde Pharmaceutical Holding Group Co Ltd, is a China-based company mainly engaged in the manufacture of pharmaceuticals and medical devices. The Company primarily operates through three segments. The Pharmaceutical Manufacturing segment is mainly engaged in the research and development, production and sales of modern Chinese medicines, chemical raw materials and chemical preparations. The Medical Device segment is mainly engaged in the research and development of medical devices, medical equipment services and provision of hospital engineering services. The Company also conducts its business through the Other segment. The Company conducts its business in the domestic and overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002082 Stock
  4. News Wanbangde Pharmaceutical Holding Group Co., Ltd.
  5. Wanbangde Pharma in Talks to Buy Controlling Stake in Consun Pharma